The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

LOS ANGELES, Dec. 13 (Xinhua) -- An injectable HIV drug with novel mechanism was named on Thursday by the influential U.S. journal "Science" as Breakthrough of the Year. The drug, named lenacapavir, ...

Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

The next year brought the breakthrough that still defines HIV treatment today: highly active antiretroviral therapy (HAART). HAART uses three or more drugs that work in at least two different ways.

Lenacapavir, Gilead Sciences’ (NASDAQ ... Ostro works with a variety of life science manufacturers on AI-driven commercialization solutions for HCPs and patients.

Lenacapavir is already approved as a treatment ... Debra ten Brink, MD, MPH, from the Optima Consortium for Decision Science within the Burnet Institute, Melbourne, Australia, whose work supports ...

Learn about the evolution of HIV/AIDS research, from early discoveries to modern treatments antiretroviral therapy, and ...

The drug called lenacapavir is already sold under the brand ... The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and ...